Identifying high-risk patients with survival less than 5 years in myelofibrosis
| Risk stratification model . | Risk group . | Median OS, y . | Pros . | Cons . |
|---|---|---|---|---|
| DIPSS14 | Intermediate-2 | 4.0 | Easy applicability based on clinical/laboratory variables | Does not include any information on genetic variables that may have significant impact on the natural history of the disease |
| High | 1.5 | |||
| DIPSS +15 | Intermediate-2 | 2.9 | Includes cytopenias and cytogenetic data | No mutational data |
| High | 1.3 | |||
| MIPSS70*16 | High | 3.1 | Includes impact of MPN driver genes and HMR† genes | No cytogenetic data |
| MIPSS70 + 2.0*17 | High | 4.1 | Cytogenetic data Driver/HMR‡ genes | |
| Very high | 1.8 | |||
| MPN personalized risk§18 | TP53/–17p/–5/–5q | 2.4 | Combination of clinical/genetic/cytogenetic data | Study heavily weighted toward PV/ET patients Copy number variation not included in most clinical NGS reports |
| Risk stratification model . | Risk group . | Median OS, y . | Pros . | Cons . |
|---|---|---|---|---|
| DIPSS14 | Intermediate-2 | 4.0 | Easy applicability based on clinical/laboratory variables | Does not include any information on genetic variables that may have significant impact on the natural history of the disease |
| High | 1.5 | |||
| DIPSS +15 | Intermediate-2 | 2.9 | Includes cytopenias and cytogenetic data | No mutational data |
| High | 1.3 | |||
| MIPSS70*16 | High | 3.1 | Includes impact of MPN driver genes and HMR† genes | No cytogenetic data |
| MIPSS70 + 2.0*17 | High | 4.1 | Cytogenetic data Driver/HMR‡ genes | |
| Very high | 1.8 | |||
| MPN personalized risk§18 | TP53/–17p/–5/–5q | 2.4 | Combination of clinical/genetic/cytogenetic data | Study heavily weighted toward PV/ET patients Copy number variation not included in most clinical NGS reports |